Twist Bioscience had its Relative Strength (RS) Rating upgraded from 80 to 83 Friday.
This proprietary rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against other publicly traded companies.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating of at least 80 as they begin their biggest runs.
Risk Management In The Stock Market: How Much Money To Invest Now
Twist Bioscience has risen more than 5% past a 43.21 entry in a first-stage cup without handle, meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
Twist Bioscience reported 0% earnings growth in the latest quarterly report. Revenue gains came in at 27%. Keep an eye out for the company's next round of numbers on or around Jan. 31.
Twist Bioscience earns the No. 124 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
